Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) EBIAT (2016 - 2026)

Gyre Therapeutics has reported EBIAT over the past 16 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly EBIAT fell 331.99% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 44.54% year-over-year, with the annual reading at $9.9 million for FY2025, 44.8% down from the prior year.
  • EBIAT was -$1.3 million for Q4 2025 at Gyre Therapeutics, down from $5.9 million in the prior quarter.
  • Over five years, EBIAT peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
  • The 5-year median for EBIAT is $1.1 million (2024), against an average of -$7.1 million.
  • Year-over-year, EBIAT crashed 453.61% in 2021 and then skyrocketed 359.09% in 2022.
  • A 5-year view of EBIAT shows it stood at -$20.3 million in 2021, then plummeted by 37.23% to -$27.9 million in 2022, then crashed by 261.95% to -$101.0 million in 2023, then soared by 100.56% to $569000.0 in 2024, then crashed by 331.99% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBIAT are -$1.3 million (Q4 2025), $5.9 million (Q3 2025), and $1.6 million (Q2 2025).